Book signing sold out at #BIO2016
My book signing sold out, but do not despair — you can still get a signed copy. Signed copies of Building […]
Featured
General Biotechnology
Come to my book signing at #BIO2016
I will be signing my textbook Building Biotechnology, and other books, in the BIO bookstore on Wednesday June 8th from 12:30 pm
General Biotechnology
Biotech in Countries Starting with “I” – Part 10: India
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
Biotech in Countries Starting with “I” – Part 10: India Read Post »
Biosimilar Naming: Distinguishable or Disingenuous?
This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a
Biosimilar Naming: Distinguishable or Disingenuous? Read Post »
Featured, General Biotechnology
When do Drug Patents Expire, and When Can Generic Drugs Launch?
[slideshare id=61425574&doc=whendodrugpatentsexpire-160427163211] When do drug patents expire, and when can generic drugs launch? An overview of patents, non-patent regulatory exclusivities,
When do Drug Patents Expire, and When Can Generic Drugs Launch? Read Post »
Mainstreaming the Microbiome
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
Which pharmaceutical companies have the most “New Dosage Form” drugs?
New Dosage Forms are one of the categories for which the FDA grants three years of exclusivity for ‘New Clinical
Which pharmaceutical companies have the most “New Dosage Form” drugs? Read Post »
General Biotechnology
Which pharma companies have the most ‘New Dosage Form’ exclusivities?
New Dosage Forms are one of the categories for which the FDA grants three years of exclusivity for ‘New Clinical
Which pharma companies have the most ‘New Dosage Form’ exclusivities? Read Post »
General Biotechnology
Bioentrepreneurship education programmes in the United States
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Bioentrepreneurship education programmes in the United States
Go to paperABSTRACT: In this first paper of a new regular column, Arlen Meyers and Patrick…
Bioentrepreneurship education programmes in the United States Read Post »
General Biotechnology
Legal and regulatory update
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Legal and regulatory update
Go to paperABSTRACT: The Office of Fair Trading (OFT) has recently found Genzyme Limited guilty of abusing its dominant posi…
